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Purpose: The purpose of this paper is discriminating between tumor progression and
response to treatment based on follow-up multi-parametric magnetic resonance imaging
(MRI) data retrieved from glioblastoma multiforme (GBM) patients.
Materials and Methods: Multi-parametric MRI data consisting of conventional MRI
(cMRI) and advanced MRI [i.e., perfusion weighted MRI (PWI) and diffusion kurtosis
MRI (DKI)] were acquired from 29 GBM patients treated with adjuvant therapy after
surgery. We propose an automatic pipeline for processing advanced MRI data and
extracting intensity-based histogram features and 3-D texture features using manually
and semi-manually delineated regions of interest (ROIs). Classifiers are trained using
a leave-one-patient-out cross validation scheme on complete MRI data. Balanced
accuracy rate (BAR)–values are computed and compared between different ROIs, MR
modalities, and classifiers, using non-parametric multiple comparison tests.
Results: Maximum BAR–values using manual delineations are 0.956, 0.85, 0.879, and
0.932, for cMRI, PWI, DKI, and all threeMRI modalities combined, respectively. Maximum
BAR–values using semi-manual delineations are 0.932, 0.894, 0.885, and 0.947, for
cMRI, PWI, DKI, and all three MR modalities combined, respectively. After statistical
testing using Kruskal-Wallis and post-hoc Dunn-Šidák analysis we conclude that training
a RUSBoost classifier on features extracted using semi-manual delineations on cMRI or
on all MRI modalities combined performs best.
Conclusions: We present two main conclusions: (1) using T1 post-contrast (T1pc)
features extracted from manual total delineations, AdaBoost achieves the highest
BAR–value, 0.956; (2) using T1pc-average, T1pc-90th percentile, and Cerebral Blood
Volume (CBV) 90th percentile extracted from semi-manually delineated contrast
enhancing ROIs, SVM-rbf, and RUSBoost achieve BAR–values of 0.947 and 0.932,
respectively. Our findings show that AdaBoost, SVM-rbf, and RUSBoost trained on T1pc
and CBV features can differentiate progressive from responsive GBM patients with very
high accuracy.
Keywords: magnetic resonance imaging, multi-parametric, boosting classifiers, glioblastoma multiforme,
follow-up
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1. INTRODUCTION
Glioblastoma multiforme (GBM) is the most common and
malignant intracranial tumor (Burger et al., 1985), representing
as much as 30% of primary brain tumors with increasing
incidence in some geographic regions (Dobes et al., 2011).
The patients have a median survival of only 10–14 months
after diagnosis with only 3–5% of patients surviving more
than three years. Recurrence is universal, and at the time
of relapse, the median survival is only 5–7 months despite
therapy (Rulseh et al., 2012). The current standard of care is
surgical resection followed by radiotherapy and concomitant
adjuvant temozolomide chemotherapy (Stupp et al., 2005).
Magnetic resonance imaging (MRI) is the most widely used
medical imaging technique for identifying the location and size
of brain tumors. However, conventional MRI (cMRI) has a
limited specificity in determining the underlying type and grade
of the brain tumor (Earnest et al., 1988; Dean et al., 1990).
More advanced MR techniques like perfusion weighted MRI
(PWI) and diffusion kurtosis MRI (DKI) are promising in the
characterization of brain tumors as they give potentially more
physiological information (Nelson and Cha, 2003; Rees, 2003;
Vrabec et al., 2011). DKI visualize the tissue structure and are
useful for assessing tumor cellularity, as it gives information
about the water movement inside different tissues including
biological barriers. Typical parameters related to diffusion are
fractional anisotropy (FA), mean diffusivity (MD), and mean
kurtosis (MK). FA is a general index of anisotropy, with a value
of zero corresponding to isotropic diffusion and a value of one
corresponding to diffusion only in one direction. MD is also a
general parameter that accounts for the mean diffusivity in all
directions, while MK might be a specific parameter for tissue
structure (Jensen et al., 2005). PWI provides measurements that
reflect changes in blood flow and blood volume. Hypervascularity
due to glioma-induced neoangiogenesis may show up as high
relative cerebral blood volume (rCBV) while necrosis of different
tissues may show up as low rCBV (Lund et al., 2005).
We studied patients with GBM that had their tumor surgically
removed and afterwards were treated according to two different
protocols developed for evaluating dendritic cell immuno-
therapy: HGG-IMMUNO-2003 (De Vleeschouwer et al., 2004,
2008; Rutkowski et al., 2004; Van Gool et al., 2009), and HGG-
IMMUNO-2010 (Van Gool et al., 2009).
The focus of this paper is the same as the focus of our
previous paper (Ion-Margineanu et al., 2015): finding a map
between multi-parametric MRI data acquired during the follow-
up of GBM patients and the relapse of brain tumor after surgery,
as described by the clinically accepted Response Assessment
in Neuro-Oncology (RANO) criteria (Wen et al., 2010). We
were motivated to conduct this study because of our excellent
previous results where we could differentiate, based only on PWI
features, between progressive and responsive follow-up GBM
patients with 100% accuracy one month before the patients were
labelled according to the RANO criteria. A major drawback of
our previous results was the small sample size (18 patients, 27
data points). In this study, we want to confirm our findings on
an extended dataset of 29 patients, which includes data from the
previous study.
Additionally, we present two main improvements: (1)
semi-manually delineating contrast enhancing region (CER)
and non-enhancing region (NER) and (2) extracting additional
texture and histogram features, with the purpose of improving
classification performance. The first improvement is to
automatically delineate CER, based on the manually delineated
total tumor region. Delineating CER by hand is a time consuming
process and requires the radiologist’s full attention to make sure
that necrosis or non-enhancing regions are not in CER. We
select CER based on the T1pc main property of imaging the
contrast agent’s leakage into the active tumor, which determines
high intensity areas where the active tumor is located. The
second improvement is extracting histogram and texture
features and selecting those with high differentiating power.
In the previous paper, we used only the average parameter
values from CER, NER, and total. In this paper, we extract
six histogram features and 20 3-D texture features based on
the gray level co-occurrence matrix (GLCM), as described in
Section 2.2.6. We do feature selection using six of the most
widely known features selection algorithms and combine
feature rankings using the rank product method, as described
in Section 2.2.8. In Section 3, linear and non-linear classifiers
are tested on a varying number of features, and their results
are combined into separate groups, which are used as input to
non-parametric statistical tests to discover which combination
of delineation, MR modality, and classifier, achieves the highest
rank.
2. MATERIALS AND METHODS
2.1. Study Setup
Twenty-nine patients were included in this study, out of which
sixteen patients were treated according to the HGG-IMMUNO-
2003 protocol (De Vleeschouwer et al., 2004, 2008; Rutkowski
et al., 2004; Van Gool et al., 2009), and 13 patients were treated
according to the HGG-IMMUNO-2010 protocol (Van Gool
et al., 2009; Ardon et al., 2010). Patients treated according
to the HGG-IMMUNO-2003 protocol had relapsed GBM and
received immunotherapy as the sole treatment strategy. Patients
treated according to the HGG-IMMUNO-2010 protocol had
primary GBM and underwent surgery. For the follow up
treatment after surgery they were split in a double blind placebo
controlled randomized clinical trial in which immunotherapy
is integrated with radiochemotherapy. At the beginning all
patients were scanned on a monthly basis, but after 6 months
under immunotherapy they were scanned once every 3 months.
The institutional human ethics review board of the University
Hospitals of Leuven (Leuven, Belgium) approved this study.
Written informed consent was obtained from every patient
before participation.
Based on radiological evaluation of the follow-up MRI scans
using the current guidelines for response assessment of high
grade glioma (Wen et al., 2010), each patient was assigned to one
of two clinical groups:
• Patients with progressive disease during follow-up which
exhibit an increase of ≥25% in the sum of the products of
perpendicular diameter of enhancing lesions compared to the
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smallest tumor measurement obtained either at baseline or
best response.
• Patients with complete response with disappearance of all
measurable and non-measurable disease sustained for at least
4 weeks.
Based on this assessment, each MRI scan of each patient
was considered labeled or unlabeled as follows: labeled as
“responsive” for all time-points at and after the moment when
the patient was considered “complete response;” labeled as
“progressive” for all time-points at and after the moment when
the patient was considered “progressive disease;” “unlabeled”
for all time-points preceding the decision moment. In total
there are 183 time points, 56 are labeled and 127 are
unlabeled.
2.2. MRI Acquisition and Processing
The MR images were acquired on a clinical 3 Tesla MR imaging
system (Philips Achieva, Best, Netherlands), using a body coil for
transmission and a 32-channel head coil for signal reception. The
imaging protocol consisted of cMRI, PWI, and DKI.
2.2.1. Conventional MRI
Four types of conventional MR images were acquired as
previously described (Vrabec et al., 2011; Van Cauter et al.,
2012, 2014): an axial spin echo T2-weighted MR image [TR/TE:
3000/80 ms, slice/gap: 4/1 mm, field of view (FOV): 230 ×
184 mm2, turbo factor (TF): 10, acquisition matrix: 400 ×
300]; an axial fluid-attenuated inversion recovery (FLAIR) image
(TR/TE/IR: 11,000/120/2800 ms, slice/gap: 4/1 mm, acquisition
matrix: 240×134) and a T1-weighted 3D spoiled gradient echo
scan (fast field echo—FFE, TR/TE: 9.7/4.6 ms, flip angle: 8◦,
turbo field echo factor: 180, acquisition voxel size: 0.98 × 0.98
× 1 mm3, 118 contiguous partitions, inversion time: 900 ms)
after contrast administration were acquired as high-resolution
anatomical reference images.
2.2.2. Perfusion MRI
PWI were obtained using a standard dynamic-susceptibility
weighted contrast perfusion MR imaging protocol consisting
of a gradient echo-EPI sequence, TR/TE: 1350/30 ms, section
thickness/gap: 3/0 mm, dynamic scans: 60, FOV: 200 × 200
mm2, matrix: 112 × 109, number of slices: 23, scan time: 1
min 26 s. EPI data were acquired during the first pass following
a rapid injection of a 0.1 mmol/kg body weight bolus of
megluminegadoterat (Dotarem, Guerbet, Villepinte, France) via
a mechanical pump at a rate of 4 ml/s, followed by a 20 ml
bolus of saline. Preload dosing was performed according to Hu
et al. in order to correct for T1-weighted leakage (preload dose
0.1 mmol/kg megluminegadoterat, incubation time 10 min) (Hu
et al., 2010). PWI were processed using the DSCoMAN plugin
(Boxerman et al., 2006) for ImageJ (http://rsb.info.nih.gov/ij/),
which takes into consideration the leakage correction and can
easily be automated. For each PWI acquisition, five parameter
maps were extracted: corrected cerebral blood volume (CBV),
cerebral blood flow (CBF), mean transit time (MTT), time to
peak (TTP), and R2.
2.2.3. Diffusion MRI
DKI data were acquired according to the previously described
protocol in Van Cauter et al. (2012, 2014) SE-EPI-DWI sequence
with TR/TE: 3200/90ms, δ/1: 20/48.3 ms; FOV: 240× 240mm2,
matrix: 96 × 96, number of slices: 44, 1 signal average acquired,
section thickness/gap: 2.5/0 mm, b-values: 0, 700, 1000, and 2800
s/mm2 in 10, 25, 40, and 75 uniformly distributed directions,
respectively (Poot et al., 2010). The DKI data were processed as
described in Van Cauter et al. (2014). For each DKI acquisition,
seven parameters maps were derived from the tensors (Jensen
et al., 2005; Hui et al., 2008): fractional anisotropy (FA), mean
diffusivity (MD), axial diffusivity (AD), radial diffusivity (RD),
mean kurtosis (MK), axial kurtosis (AK), radial kurtosis (RD).
2.2.4. Delineations
A regions of interest (ROI) was manually drawn around the Total
tumor lesion, avoiding areas of necrosis, or cystic components
such as the surgical cavity. A separate ROI was drawn around
the contra-lateral normal appearing white matter (NAWM) to
standardize measurements extracted from the tumor region. The
Total and NAWM ROIs were drawn by SVC, a radiologist with 5
years experience.
To automatically split the Total region in two ROIs, CER
and NER, a threshold was set at the 90th percentile of T1pc
Total voxels. In this way, two semi-manual ROIs were made for
each patient based on the T1pc intensities selected from Total:
CER, containing very high T1pc intensity Total voxels, and NER,
containing the rest of Total voxels.The 90th percentile threshold
was selected after visually inspecting T1pc maps of multiple
patients.
A typical example of manual and semi-manual ROIs on T1pc
can be seen in Figure 1, where red is CER and blue is NER.
2.2.5. Co-registration
All four cMRI maps, T1, T1pc, T2, and FLAIR, were first skull-
stripped using FSL-BET with default parameters (Smith, 2002).
Afterwards, affine co-registration of skull-stripped T1, T2, and
FLAIR to skull-stripped T1pc was done using NiftyReg (Ourselin
et al., 2002) with default parameters (http://cmictig.cs.ucl.ac.uk/
wiki/index.php/NiftyReg). Three affine transformation matrices
were saved and used to re-sample the corresponding original T1,
T2, and FLAIR to the T1pc space.
To co-register PWI a similar protocol was used. Each PWI
scan has 60 T2∗ brain volumes that can be selected to be
FIGURE 1 | (Left) T1pc. (Center) Manual delineations on top of T1pc.
(Right) Semi-manual delineations on top of T1pc. CER is red and NER is blue.
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co-registered to T1pc. In this study, we select the first PWI
brain volume and assume that the rest of them are well-aligned
with it, ignoring any artifacts. After skull-stripping the first
PWI volume using FSL-BET with default parameters, affine co-
registration to skull-stripped T1pc was done using NiftyReg with
default parameters. We obtain one affine transformation that is
used to co-register all five PWI parameter maps (described in
Subsection 2.2.2) to T1pc.
To co-register DKI a similar protocol was used. EachDKI scan
has 10 T2 brain volumes that can be selected to be co-registered
to T1pc. In this study, we select the first DKI brain volume and
assume that the rest of them are well aligned with it, ignoring
any artifacts. After skull-stripping the first DKI volume using
FSL-BET with default parameters, affine co-registration to skull-
stripped T1pc was done using NiftyReg with default parameters.
We obtain one affine transformation that is used to co-register
all seven DKI parameter maps (described in Subsection 2.2.3)
to T1pc.
Visual inspection of the tumor’s center in the axial plane of all
maps for all patients after co-registration to T1pc was done by
AIM and found no major misalignments. An example of all 16
maps for a random patient can be seen in Figure 2.
FIGURE 2 | Example of co-registration results for all multi-parametric
MR maps.
2.2.6. Feature Extraction
After co-registering all maps to T1pc, the three ROIs (Total,
CER, NER) are used as separate 3-D masks on each map to
extract histogram and texture features. On each map, voxel
intensities from each mask were normalized to the average
value computed from the corresponding NAWM ROI. For each
mask six histogram measures are computed: mean, coefficient of
variation, 90th percentile, 10th percentile, skewness, and kurtosis.
Additionally, 20 texture features are extracted from the 3-D
GLCM (Haralick et al., 1973). To compute the GLCM, each map
has been rescaled such that the voxel intensities are integers
varying from 1 to 64.
The GLCM computation was done using the function
graycomatrix implemented in Matlab R2015a (MathWorks,
Massachusetts, U.S.A.) with distance set to 1, the “Symmetric”
flag set to true, and four values of “Offset” set to the four
main directions: 0◦, 45◦, 90◦, and 135◦. Twenty 3-D texture
features, as described in Haralick et al. (1973), Soh and
Tsatsoulis (1999), and Clausi (2002), were extracted from GLCM:
autocorrelation, contrast, correlation, cluster prominence, cluster
shade, dissimilarity, energy, entropy, homogeneity, maximum
probability, sum of squares: variance, sum average, sum variance,
sum entropy, difference variance, difference entropy, information
measure of correlation (IMC) 1 and 2, inverse difference
normalized (IDN), and inverse difference moment normalized
(IDMN).
In the end 416 features are extracted from each ROI: 26
histogram and texture features for each of the 16 maps. All
features have been rescaled between 0 and 1, using all 183 labeled
and unlabeled time points. In total, our dataset has 56 data points
and 1248 features.
2.2.7. Datasets Comparison
In this study we analyze two main influences: (1) features
extracted from CER&NER vs. features extracted from Total
tumor; (2) cMRI vs. PWI vs. DKI vs. all multi-parametric
MRI features (cPD). Therefore, we split the original dataset
according to the two main influences and create eight smaller
datasets. These eight datasets were built using complete labeled
time points, meaning labeled time points which have all MRI
data available. Only complete time points were selected because
in order to have a fair comparison between different MRI
modalities, the number of points must not differ between them.
All eight datasets have acquisitions from 29 patients and 55
time points. The ratio between progressive and responsive time
points is slightly unbalanced, 34–21, or 62 vs. 38%.Table A1 from
Appendix I shows the number of features in each dataset.
2.2.8. Feature Selection Methods
In order to avoid the curse-of-dimensionality (Bellman, 2015),
the number of data points should be much larger than the
number of features. Because there are only 55 data points,
different feature selection methods were used to reduce the
dimension between 1 and 10 (Hua et al., 2005). In this study, six
of the most widely known feature selection algorithms were used:
minimum redundancy maximum relevance (mRMR) (Ding and
Peng, 2005), RELIEFF (Kononenko et al., 1997), information gain
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(InfoGain) (Yang and Pedersen, 1997), Pearson’s Chi2 (Yang and
Pedersen, 1997), random forest—mean decrease in accuracy (RF-
MDA) (Breiman, 2001), and random forest—mean decrease in
Gini (RF-MDG) (Breiman, 2001; Calle and Urrea, 2011). The
first four methods were run using the WEKA (Hall et al., 2009)
application program interface (API) in Matlab R2015a. The last
two methods were run using a random forest (RF) of 10,000
trees in the statistical environment R (Liaw and Wiener, 2002).
Principal component analysis or other dimension reduction
methods are not used because the biomedical meaning of the
extracted features is lost.
2.2.9. Cross Validation and Performance Measure
Given the fact that multiple data points per patient were acquired
from 29 patients, a leave one patient out cross validation
(LOPOCV) setup is used. In this way, 29-folds are created in
which the test patient is always independent of the training
patients: in each fold data points from one patient are considered
test points, while data points from the remaining 28 patients are
used for training.
In this study, two LOPOCV rounds are done, one for feature
selection, and another one for classification using fixed feature
sets.
In the first round, feature rankings are learned on the training
sets, with the most important features at the top, and the least
important at the bottom. Because each fold will have six different
feature rankings as outputs from mRMR, Relieff, InfoGain, Chi2,
RF-MDA, and RF-MDG, each dataset will have 174 feature
rankings. Combining different rankings is done by computing
rank products (Breitling et al., 2004) of each feature that appears
at least once in top 10 of any feature ranking. The output of the
first round of LOPOCV is a fixed set of 10 features selected by
rank products per dataset shown in Table A4 from Appendix I.
In the second round, increasing number of features from 1 to
10 were used to classify data points. Classifiers are trained on the
training set of each fold, then they assign a label to each testing
data point from the test set. The assigned labels are compared to
the true labels by measuring the balanced accuracy rate (BAR) of
all 55 test points. BAR, defined as the average between sensitivity
and specificity, was preferred as a performance measure because
the interest is in classifying correctly both labels (responsive and
progressive). BAR can take values between 0 and 1, 1 pointing to
a perfect classification, and 0 to a completely wrong classification.
A random classifier should give a BAR–value of 0.5.
2.3. Classifiers
Several supervised classifiers have been used, with the goal of
testing if data labeled according to the RANO criteria could have
been reliably labeled using histogram and 3-D texture measures
extracted from multi-parametric MRI. The list of classifiers as
well as their software implementation environment is presented
in Table A2, Appendix I.
The list of classifiers in Table A2 is representative for most
of the classification algorithms, starting from simple linear
ones such as Linear Discriminant Analysis (LDA) and Support
Vector Machines with linear kernel (SVM-lin) up to more
complex non-linear classifiers such as RF and Stochastic Gradient
Boosting (SGB).
Fisher’s LDA (Fisher, 1936) is a classifier that finds a linear
combination of input features that best separates the two classes.
It is also very easy to use as there are no parameters that
need to be set. Support Vector Machines (Cortes and Vapnik,
1995; Cristianini and Shawe-Taylor, 2000) is among the most
popular machine learning models because of its simplicity: given
a training set with points from two classes, it tries to find the
best hyperplane to differentiate between the two types of points.
It can be used in the original feature space or the points can be
mapped to another space by using kernel transformations. Two
types of SVM kernel were used in this study: linear (SVMlin)
and radial basis function (SVMrbf) with default settings (“C” and
“sigma” set to 1). Random forests (Breiman, 1996, 2001) are part
of the ensemble methods for classification that use a collection
of decision trees. Each decision tree learns a rule on a bootstrap
sample of the original dataset and then it can classify a new point.
The new point is assigned to the class voted by the majority
of the trees. In this study, RF was run with 1000 trees on all
input features and “class_weight” set to “balanced_subsample,” to
adjust weights for each data point inversely proportional to class
frequencies for each individual tree. Boosting algorithms (Freund
and Schapire, 1995; Seiffert et al., 2008) start with a collection of
weak classifiers, in this case decision trees, and with each iteration
they try to improve the overall classification by learning what
was misclassified at the previous step. In this paper, the boosting
algorithms had the following parameters: AdaBoost was run with
1000 trees; SGB was run with 1000 trees, “learning_rate” set to 0.1
(default), and “subsample” set to 0.5, as suggested in Friedman
(2002) Random Under Sampling Boosting (RUSBoost) was run
with 1000 trees and “LearnRate” set to 0.1.
3. RESULTS
We compared seven classifiers, four MR modalities, two types
of delineations, with a variable number of features from one
to ten, summing up to a total of 560 BAR–values. These BAR–
values were grouped in several ways (e.g., 56 groups of 10 values),
and then a non-parametric comparison was made to account
for statistical differences between groups. Multiple Kruskal
and Wallis (1952) rank tests were run in MATLAB R2015a to
determine if all groups originate from the same distribution,
followed by Dunn-Šidák’s post-hoc test (Dunn, 1964; Šidák, 1967)
to determine which group had the highest rank (better accuracy
results). The relationship between BAR–values and ranks is as
follows: each BAR–value is assigned a rank value, ignoring group
membership. The assigned rank should be an integer, except for
the case when there are multiple equal BAR–values, then the
assigned rank is the average of the individual ranks. For example,
the BAR sequence [0.5, 0.7, 0.7, 0.9] is transformed into the rank
sequence [1, 2.5, 2.5, 4].
Figures 3–6 show rank estimates and intervals of different
groups. Intervals are shown as horizontal lines, while rank
estimates are in the middle of the intervals. In each figure, the
highest ranked group has its interval limited by two vertical
dotted lines. Groups that are significantly different from the
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FIGURE 3 | Rank estimates and intervals for all combinations of classifiers, delineations, and MR modalities.
FIGURE 4 | Rank estimates and intervals for all combinations of
delineations and MR modalities.
highest ranked group have a filled diamond marker in the middle
of their interval, while groups that are not significantly different
from the highest ranked group have an empty circular marker in
themiddle of their interval. Two groups are significantly different
if their intervals are disjoint; they are not significantly different if
their intervals overlap.
Figure 3 shows 56 groups, each group containing 10 BAR–
values coming from test runs with varying only the number of
features. In the upper part there are 28 groups using CER&NER
features, while in the lower part there are 28 groups using Total
tumor features. The highest ranked group is CER&NER-cMRI-
RUSBoost and its rank is significantly higher than 18 out of 28
groups achieved with Total tumor features.
Figure 4 shows eight groups, each group containing 70 BAR–
values coming from test runs with varying classifiers and number
FIGURE 5 | Rank estimates and intervals for all combinations of
delineations and classifiers.
of features. In the upper part there are four groups using
CER&NER features, while in the lower part there are four
groups using Total tumor features. The highest ranked group has
CER&NER-cMRI features and its rank is significantly higher than
all groups using Total tumor features. Moreover, the CER&NER-
cMRI group has a significantly higher rank than CER&NER-PWI
andCER&NER-DKI. Thismeans that classification based only on
conventional MRI features performs better than the classification
based only on perfusion or diffusion features.
Figure 5 shows 14 groups, each group having 40 BAR–
values coming from test runs with varying MR modalities and
number of features. In the upper part there are seven groups
using CER&NER features, while in the lower part there are
seven groups using Total tumor features. The highest ranked
group is CER&NER-RUSBoost and its rank is significantly
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higher than all groups using Total tumor features except
AdaBoost.
Figure 6 shows 20 groups, each group having 28 BAR–values
coming from test runs with varyingMRmodalities and classifiers.
In the upper part there are 10 groups using CER&NER features,
while in the lower part there are 10 groups using Total tumor
features. The highest ranked group is CER&NER-Number of
features:3 and its rank is significantly higher than all groups using
Total tumor features except Total-Number of features:4.
Figure 7 shows the maximum BAR over all MRmodalities for
CER&NER and Total tumor ROIs, when varying the number of
features from 1 to 10. In Appendix I, associated with Figure 3,
there is Table A3. Figures A1, A2 from Appendix I show results
of each classifier when varying the number of features from 1 to
10 for each MR modality, for CER&NER and Total tumor ROIs,
respectively.
Multiple remarks can be made after analyzing the figures
and tables previously presented. One of the most important
remarks is that there is no combination of features, classifier,
and delineations, that gives a perfect BAR–value of 1. Although
all post-hoc tests show the superiority of features extracted
from contrast-enhancing and non-enhancing regions, the highest
BAR–value is achieved using total tumor features. To compare,
the highest BAR–value obtained using total tumor features is
0.956, with AdaBoost on cMRI, between 7 and 9 features, while
the highest BAR–value obtained using contrast-enhanced and
non-enhanced features is 0.947, with SVMrbf trained on the first
three cPD features. It is interesting to note that the maximum
BAR–value using total tumor features is achieved using only
T1pc features, while the maximum BAR–value using contrast-
enhanced and non-enhanced features is achieved only after
combining perfusion features with T1pc features. To be more
specific, the maximum BAR–value using contrast-enhanced and
non-enhanced features is achieved only after training SVMrbf
on the following three features: T1pc-average-CER, T1pc-
90th_percentile-CER, and CBV-90th_percentile-CER.
Another notable result is the fact that RUSBoost trained
only on just one feature (T1pc-Average-CER) achieves a
remarkable BAR–value of 0.932. This BAR–value is maintained
by RUSBoost trained on all 10 contrast-enhanced and non-
enhanced conventional MRI features, indicating a robust
classification. The same BAR–value of 0.932 is achieved by
RUSBoost also on the first five CER&NER-cPD features, which
are histogram features extracted from T1pc, CBV, and CBF.
When we add the sixth cPD feature, a diffusion texture feature
(ak-IMC2-CER), the BAR–value drops to 0.86.
The post-hoc results reflect the consistent high BAR–values
of RUSBoost trained on contrast-enhanced and non-enhanced
features, placing it at the two highest ranked positions in
Figure 3. Although no group is significantly higher than the rest
of groups, CER&NER-cMRI-RUSBoost is ranked significantly
higher than most of Total-PWI and Total-DKI classifiers.
Top two classifiers using Total tumor features that are not
significantly different than CER&NER-cMRI-RUSBoost are
Total-AdaBoost-cMRI and Total-AdaBoost-cPD.
Figure 4 shows a surprising result: the best ranked group,
compared to all but one, is CER&NER-cMRI. This is surprising
because it means that there is no need to acquire perfusion
or diffusion MRI, one can obtain high BAR–values using
only conventional MRI features. Although we are aware that
the highest BAR–value using contrast-enhanced and non-
enhanced features was obtained after combining perfusion
and conventional MRI features, BAR–values obtained
only on CER&NER-PWI or CER&NER-DKI features were
ranked significantly lower than CER&NER-cMRI. BAR–
values obtained using Total tumor features with any kind
of MR modality were also ranked significantly lower than
CER&NER-cMRI.
FIGURE 6 | Rank estimates and intervals for all combinations of delineations and varying number of features.
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FIGURE 7 | Maximum classification results over all MR modalities using 1–10 features. On y-axis are BAR–values, and on x-axis the number of features used
for classification.
Analyzing Figure 5 we can make two remarks: RUSBoost is
the best classifier using contrast-enhanced and non-enhanced
features and AdaBoost is the best classifier using total tumor
features. Analyzing Figure 6 we see that for CER&NER,
increasing the number of features above a threshold of 3 will
decrease the BAR–values, although not significantly.
It is clear from these four figures, Figures 3–6 that splitting
the total tumor into two regions, contrast-enhancing and non-
enhancing, using a simple threshold like 90th percentile, can
improve significantly the classification accuracy.
4. DISCUSSION
In Table A4 we can see that feature selection for contrast-
enhanced and non-enhanced features revealed an interesting
result: only one feature was selected from the non-enhancing
group (for DKI, 8th position). This means that contrast-
enhancing features are very meaningful and we could rely only
on them in future works involving classification or statistical
analysis.
When comparing the number of features selected from
histogram or texture, even though we extracted more texture
features (20 compared to 6), we can see a relative balance in all
MR modalities except DKI. In top 10 CER&NER-cMRI features,
4 come from histogram; in top 10 CER&NER-PWI features, 4
come from histogram; in top 10 CER&NER-cPD features, 6 come
from histogram; in top 10 CER&NER-DKI features, only 1 comes
from histogram. In top 10 Total-cMRI features, 4 come from
histogram; in top 10 Total-PWI features, 2 come from histogram;
in top 10 Total-cPD features, 5 come from histogram; in top 10
Total-DKI features, none come from histogram. These feature
rankings strongly suggest that if only DKI data is available,
one should definitely extract texture features to assess tumor
recurrence.
When selecting cPD features, for both CER&NER and Total
tumor ROIs, we can see in top 5 the same two features: T1pc-
90th_percentile and CBV-90th_percentile. This selection comes
as a confirmation of the majority of literature articles showing
that contrast enhancement areas and CBV–values are strongly
correlated to tumor progression (Lund et al., 2005; Barajas Jr.
et al., 2009; Hu et al., 2012, 2011). The main reason behind this
strong correlation is the fact that tumors grow uncontrollably,
so they require more nutrients compared to surrounding tissue,
which is reflected in the tumor’s angiogenesis. The increase in
angiogenesis is visualized and measured using T1pc and PWI.
There are multiple studies that focus on predicting the
treatment outcome of follow-up GBM patients using multi-
parametric MR data. The majority focuses mainly on overall
survival, true progression vs. pseudo-progression or true
progression vs. radiation injury. Some recent examples are
the following Elson et al. (2015) show using DKI data from
52 patients that Apparent Diffusion Coefficient (ADC)–values
strongly correlate to overall survival Smets et al. (2013) conclude
on 24 patients that absence of contrast enhancement on
immediately post-operative T1pc correlates to an increase in
overall survival Zhang et al. (2016) developed a new feature
selection method using DKI data from 79 patients which gives
an area under the receiver operating characteristic (ROC) curve
(AUC) of 0.86 for separating true from pseudo-progression,
without any manual segmentation; Bulik et al. (2015) found
significant differences in ADC and spectroscopic metabolites
values between patients with true and pseudo-progression
Di Costanzo et al. (2014) show, using data from 29 patients,
that LDA trained on ADC, CBV, and normalized Choline gives
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a 96.6% accuracy in differentiating patients with true progression
vs. radiation injury Khalifa et al. (2016) show that the fraction
of hypoperfused tumor volume gives a 79.2% accuracy in
anticipating tumor relapse at the next follow-up point.
Our study is, to our best knowledge, the only one that tries to
classify progressive vs. responsive follow-up GBM patients based
on multi-parametric MR data acquired at 3T. In our previous
paper we showed, using data from 18 patients, that PWI is a
very powerful predictor of tumor recurrence, obtaining 100%
accuracy in predicting the label one month before the label was
put according to RANO criteria. In this paper, we used data
acquired from 29 patients, therefore the classification problem
is more difficult because of the increasing overlap between
the classes. However, we still obtained maximum BAR–values
higher than 0.85 for each dataset: (i) Contrast-enhancing and
Non-enhancing features - cMRI-0.932, PWI-0.894, DKI-0.885,
cPD-0.947; (ii) Total tumor features—cMRI-0.956, PWI-0.85,
DKI-0.879, and cPD-0.932. Although the maximum value is
achieved using features extracted from Total tumor ROI and not
CER&NER (0.956 vs. 0.947), we showed using non-parametric
multiple comparison tests that it is recommended to use features
from CER&NER, which could be defined by a simple threshold
like the 90th percentile on T1pc-Total ROI.
5. CONCLUSIONS
We proposed an automatic pipeline for processing multi-
parametric MR data acquired at 3T and validated it after
extracting histogram and GLCM 3-D texture features. We
determined the added value of extracting features from
semi-manually delineated contrast-enhancing and non-
enhancing ROIs compared to features extracted from manual
total tumor ROIs using non-parametric multiple comparison
tests. We showed that AdaBoost, RUSBoost, and SVM-rbf
trained mainly on features extracted from T1pc and CBV
maps achieve the highest ranked performance in classifying
progressive vs. responsive follow-up GBM patients. Finally, our
results suggest that using only conventional MRI features is
better than using only perfusion or diffusion MRI features in the
same classification problem.
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APPENDIX I
TABLE A1 | Number of features per MRI modality and delineation.
CER&NER Total ROI
cMRI PWI DKI cPD cMRI PWI DKI cPD
Number of
features
208 260 364 832 104 130 182 416
TABLE A2 | Supervised classifiers.
Classifiers Software
Linear Discriminant Analysis (LDA) Matlab R2015a—Statistics and Machine
Learning Toolbox
Support Vector Machine (SVM) Matlab R2015a—Statistics and Machine
Learning Toolbox
Random Forests (RF) Python 2.7.6—sklearn.ensemble.
RandomForestClassifier






Random Under Sampling Boosting
(RUSBoost)
Matlab R2015a—Statistics and Machine
Learning Toolbox
TABLE A3 | Maximum BAR of all MR modalities over all classifiers.
Dataset Number of features cMRI PWI DKI cPD
CER&NER 1 0.9321 0.8936 0.8571 0.9321
2 0.9321 0.8459 0.8277 0.9321
3 0.9321 0.8550 0.8662 0.9468
4 0.9321 0.8256 0.8606 0.9321
5 0.9321 0.8403 0.8606 0.9321
6 0.9321 0.8697 0.8368 0.8606
7 0.9321 0.8312 0.8368 0.8606
8 0.9321 0.8221 0.8368 0.8606
9 0.9321 0.8221 0.8221 0.8606
10 0.9321 0.8312 0.8845 0.8606
Total ROI 1 0.8018 0.7598 0.8459 0.8459
2 0.8789 0.7836 0.8368 0.8368
3 0.8200 0.7836 0.8550 0.8606
4 0.8312 0.7927 0.8165 0.8992
5 0.9412 0.7689 0.8165 0.8754
6 0.9412 0.8494 0.8789 0.8754
7 0.9559 0.8403 0.8459 0.8606
8 0.9559 0.7927 0.8312 0.9321
9 0.9559 0.7927 0.7780 0.8845
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FIGURE A1 | Classification results on CER & NER semi-manual delineations, using 1–10 features assigned by rank products per each dataset. On
y-axis are BAR–values, and on x-axis the number of features used for classification.
FIGURE A2 | Classification results on Total manual delineations, using 1–10 features assigned by rank products per each dataset. On y-axis are
BAR–values, and on x-axis the number of features used for classification.
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